THE SCIENCE OF KAVA

Professor Sarris is a NHMRC (National Health and Medical Research Council) Clinical Research Fellow, Professor of Integrative Mental Health and Deputy Director of NICM Health Research at Western Sydney University, Australia. He is also an honorary Principal Research Fellow with the Department of Psychiatry at Melbourne University.

As well as being our Scientific Advisor to Fiji Kava, Professor Sarris is also a Scientific Advisor to medicinal cannabis company ANTG.

Watch Professor Jerome Sarris present key findings and research regarding kava in the videos below.

Our kava products are produced by high-quality GMP. Research exists showing that Noble kava can be effective in reducing anxiety and stress:

The first double-blind, placebo controlled, cross-over clinical trial took place in 2008 2009 in Australia, with the results demonstrating that kava (250mg of kavalactones) significantly reduced anxiety over a 3-week period in 60 adults (Sarris et al., 2009).

A follow-up 6-week study in 75 participants diagnosed with generalised anxiety disorder further demonstrated the effect of kava (120mg-240mg of kavalactones) in significantly reducing anxiety compared to placebo (Sarris et al., 2013a).

Notably, in both studies there were no significant effects of kava on liver function or any adverse liver effects (Sarris et al., 2013b).

Together this data indicates that not only is a water-soluble root extract of a noble cultivar of kava a fast-acting effective anxiolytic, but it also produces less unfavourable side effects compared to conventional pharmacotherapies, and is (in these small samples) safe on the liver.